Brief: Biofrontera Announces Progress Of Phase III Study For Treatment Of Sbcc With Ameluz®
01/02/2022 13:33
Feb 1 (Reuters) - BIOFRONTERA AG B8FGn.DE :
* BIOFRONTERA ANNOUNCES PROGRESS OF PHASE III STUDY FOR
TREATMENT
OF SBCC WITH AMELUZ®
* TO DATE, 70% OF PLANNED 186 PATIENTS HAVE BEEN ENROLLED IN
STUDY
WITH COMPLETION OF PATIENT RECRUITMENT ANTICIPATED BY END OF
2022
Source text for Eikon: ID:nPex3RJBya
Further company coverage: B8FGn.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Biofrontera AG
See all newsBrief: Biofrontera Says Co And Units Have Entered Into An Agreement With Biofrontera Inc About How To Settle Payment Obligations By Biofrontera Inc
Brief: Biofrontera AG Says Legal Dispute On Import In USA Will Result In Revised Outlook
Brief: Biofrontera AG Resolves Capital Increase From Authorized Capital
Brief: Biofrontera AG Says Plans Capital Reduction And Considers Subsequent Capital Increase From Authorized Capital
Brief: Biofrontera AG Says FY 2022 Total Revenue Amounted To EUR 25.7 Million